202 related articles for article (PubMed ID: 33742986)
21. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
22. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
23. The genomics of renal cell carcinoma and its role in renal mass biopsy.
Salami SS; George AK; Udager AM
Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.
Manley BJ; Hakimi AA
Curr Opin Urol; 2016 Sep; 26(5):383-7. PubMed ID: 27467134
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
27. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
28. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
29. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
30. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
31. Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
Nakayama T; Saito K; Kumagai J; Nakajima Y; Kijima T; Yoshida S; Kihara K; Fujii Y
Clin Genitourin Cancer; 2018 Dec; 16(6):e1151-e1158. PubMed ID: 30213543
[TBL] [Abstract][Full Text] [Related]
32. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
34. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
[TBL] [Abstract][Full Text] [Related]
35. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bedke J; Capitanio U; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Klatte T; Kuusk T; Lam TB; Marconi L; Powles T; Tahbaz R; Volpe A; Bex A
Eur Urol; 2022 Oct; 82(4):399-410. PubMed ID: 35346519
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
37. Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma.
Morin E; Lindskog C; Johansson M; Egevad L; Sandström P; Harmenberg U; Claesson-Welsh L; Sjöberg E
J Pathol; 2020 Apr; 250(4):387-396. PubMed ID: 31880322
[TBL] [Abstract][Full Text] [Related]
38. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Bilen MA; Carlisle JW; Sonpavde G
Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
40. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
